RSRichard R. Stein

Richard R. Stein

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Richard R. Stein has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Experimental Conditions to Retrieve Intrinsic Cooperativity α Directly from Single Binding Assay Data Exemplified by the Ternary Complex Formation of FKBP12, MAPRE1 and Macrocyclic Molecular Glues

    by Jan Schnatwinkel, Richard R. Stein, Michael Salcius, Julian L. Wong, Shu-Yu Chen, Marianne Fouché, Hans-Joerg Roth

    The incorporation of disease-relevant targets into ternary complexes in a compound-dependent manner by utilizing an assisting chaperone has become a common modality as far as bifunctional ternary complex-forming compounds are concerned. In contrast, examples of ternary complexes formed by molecular glues are much rarer. Due to their lack of significant binary (independent) target affinity, their identification cannot yet be achieved by rational methods and is, therefore, much more challenging. However, it is precisely for that reason (given the associated advantages) that their systematic identification and application in drug discovery has recently attracted particular interest. In contrast to bifunctional ternary complex-forming compounds, molecular glues retrieve a significant part of their thermodynamic stability through newly induced chaperone–target or glue–target interactions that occur only in the ternary complex. These interactions lead to enhanced ligand binding—termed intrinsic cooperativity α—which can be retrieved via the apparent cooperativity either by monitoring ligand binding through the chaperone or through the target protein. In this publication, the advantage of measuring the apparent cooperativity (to determine the cooperativity α) by the weaker binding protein is discussed and illustrated using the example of ternary complexes between FKBP12, MAPRE1 and macrocyclic molecular glues derived from the rapamycin binding motif for FKBP12. Furthermore, the impact of the following three parameters on the apparent cooperativity is illustrated: (1) the concentration of the monitoring protein, (2) the excess of the counter protein, and (3) the affinity of the glue to the weaker binding protein in combination with the degree of intrinsic cooperativity α. From this, experimental conditions to determine the intrinsic cooperativity α with only one binding assay and without the need for a comprehensive mathematical model covering all simultaneous events under non-saturating conditions are highlighted. However, this framework requires a binding assay capable of measuring or at least estimating very weak binary affinities. If this is not possible for experimental reasons, but binding assays for both proteins are available within a normal bandwidth and the affinity to the stronger binding protein is not too high, it is discussed how the binding curve for the weaker binding protein in the presence of an excess of the weaker binding protein can be used to overcome the missing binary Kd for the weakly binding protein.


  • Open Access

    Effect of Target‐Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function

    by Elise Burmeister Getz, Richard R. Stein, Martin Fink, Kenneth Kulmatycki, Irina Baltcheva, Wendy Weis, Bharti Shah, Eric Lawitz, Robert Schmouder

    Iptacopan, a first‐in‐class complement factor B inhibitor acting proximally in the alternative complement pathway, has been shown to be safe and effective for patients with complement‐mediated diseases. Iptacopan selectively binds with high affinity to factor B, a soluble, plasma‐based, hepatically produced protein. Factor B is abundant in the circulation but can be saturated at the iptacopan clinical dose of 200 mg twice daily. Iptacopan pharmacokinetics (PK) are influenced by target binding. This target‐mediated drug disposition (TMDD) behavior makes PK data useful for understanding target occupancy and motivates modeling of drug‐target binding to connect exposure with pharmacological effect. A phase I hepatic impairment (HI) PK study measuring both total and unbound iptacopan PK profiles provided an opportunity to characterize the effect of variation in target concentration (due to varying hepatic function) on iptacopan PK. HI caused no change in total iptacopan exposure but increased unbound iptacopan exposure 1.38‐ to 3.72‐fold in participants with mild, moderate, or severe HI relative to demographically matched participants with normal hepatic function, with the largest increases in severe HI. A two‐site competitive binding model was developed to elucidate the relationship between iptacopan PK and factor B occupancy to characterize exposure thresholds for maximal target engagement. The model was used to assess alternative dose regimens to provide insight into how to approach dose recommendations for patients with severe HI. This study provides an example of small‐molecule TMDD, a behavior typically associated with targeted biologics; its importance is too often underappreciated in small‐molecule drug development.


  • Open Access

    Experimental conditions to retrieve intrinsic cooperativity α directly from single binding assay data exemplified by the ternary complex formation of FKBP12, MAPRE1 and macrocyclic molecular glues

    by Jan Schnatwinkel, Richard R. Stein, Michael Salcius, Julian Wong, Shu-Yu Chen, Marianne Fouché, Hans-Joerg Roth

    The incorporation of disease-relevant targets in a compound-dependent manner into ternary complexes with an assisting chaperone protein has become a common modality. Among the various types of ternary complex-forming compounds, molecular glues are of particular interest because they do not require significant binary (independent) target affinity. Instead, ternary complexes formed by molecular glues retrieve a significant part of their thermodynamic stability through newly induced chaperone–target or glue–target interactions that occur only in the ternary complex. These interactions lead to enhanced ligand binding – termed intrinsic cooperativity α – which can be retrieved via the apparent cooperativity either by monitoring ligand binding through the chaperone or through the target protein. In this publication, the advantage of measuring the apparent cooperativity to determine the cooperativity α by the weaker binding protein is discussed and illustrated using the example of ternary complexes between FKBP12, MAPRE1 and macrocyclic molecular glues derived from the rapamycin binding motif for FKBP12. Furthermore, the impact of the following three parameters on the apparent cooperativity is illustrated: 1.) the concentration of the monitoring protein, 2.) the excess of the counter protein, 3.) the affinity of the glue to the weaker binding protein in combination with the degree of intrinsic cooperativity α. From this, experimental conditions to determine the intrinsic cooperativity α with only one binding assay and without the need for a comprehensive mathematical model covering all simultaneous events under non-saturating conditions are highlighted. However, this framework requires a binding assay capable of measuring or at least estimating very weak binary affinities. If this is not possible for experimental reasons, but binding assays for both proteins are available within a normal bandwidth and the affinity to the stronger binding protein is not too high, it is discussed how the binding curve for the weaker binding protein in the presence of an excess of the weaker binding protein can be used to overcome the missing binary K d for the weakly binding protein.

  • Open Access

    A model-informed method to retrieve intrinsic from apparent cooperativity and project cellular target occupancy for ternary complex-forming compounds

    by Richard R. Stein, Marianne Fouché, Jeffrey D. Kearns, Hans-Joerg Roth

    There is an increasing interest to develop therapeutics that modulate challenging or undruggable target proteins via a mechanism that involves ternary complexes. In general, such compounds can be characterized by their direct affinities to a chaperone and a target protein and by their degree of cooperativity in the formation of the ternary complex. As a trend, smaller compounds have a greater dependency on intrinsic cooperativity to their thermodynamic stability relative to direct target (or chaperone) binding. This highlights the need to consider intrinsic cooperativity of ternary complex-forming compounds early in lead optimization, especially as they provide more control over target selectivity (especially for isoforms) and more insight into the relationship between target occupancy and target response via estimation of ternary complex concentrations. This motivates the need to quantify the natural constant of intrinsic cooperativity (α) which is generally defined as the gain (or loss) in affinity of a compound to its target in pre-bound vs. unbound state. Intrinsic cooperativities can be retrieved via a mathematical binding model from EC50 shifts of binary binding curves of the ternary complex-forming compound with either a target or chaperone relative to the same experiment but in the presence of the counter protein. In this manuscript, we present a mathematical modeling methodology that estimates the intrinsic cooperativity value from experimentally observed apparent cooperativities. This method requires only the two binary binding affinities and the protein concentrations of target and chaperone and is therefore suitable for use in early discovery therapeutic programs. This approach is then extended from biochemical assays to cellular assays (i.e., from a closed system to an open system) by accounting for differences in total ligand vs. free ligand concentrations in the calculations of ternary complex concentrations. Finally, this model is used to translate biochemical potency of ternary complex-forming compounds into expected cellular target occupancy, which could ultimately serve as a way for validation or de-validation of hypothesized biological mechanisms of action.


  • Open Access

    High-Dimensional Analysis of Immune Cell Composition Predicts Periprosthetic Joint Infections and Dissects Its Pathophysiology

    by Maximilian F. Korn, Richard R. Stein, Andreas Dolf, Farhad Shakeri, Andreas Buness, Cäcilia Hilgers, Werner Masson, Sascha Gravius, Hendrik Kohlhof, Christof Burger, et al.

    Accurate diagnosis of periprosthetic joint infections (PJI) is one of the most widely researched areas in modern orthopedic endoprosthesis. However, our understanding of the immunological basis of this severe complication is still limited. In this study, we developed a flow cytometric approach to precisely characterize the immune cell composition in periprosthetic joints. Using high-dimensional multi-parametric data, we defined, for the first time, the local immune cell populations of artificial joints. We identified significant differences in the cellular distribution between infected and non-infected samples, and revealed that myeloid-derived suppressor cells (MDSCs) act as potential regulators of infiltrating immune cells in PJI. Further, we developed an algorithm to predict septic and aseptic samples with high sensitivity and specificity, that may serve as an indispensable addition to the current criteria of the Musculoskeletal Infection Society. This study describes a novel approach to flow cytometrically analyze the immune cell infiltrate of joint fluid that not only improves our understanding of the pathophysiology of PJI, but also enables the development of a novel screening tool to predict infection status. Our data further suggest that pharmacological targeting of MDSCs represents a novel strategy for addressing PJI.


  • Open Access

    Perturbation biology links temporal protein changes to drug responses in a melanoma cell line

    by Elin Nyman, Richard R. Stein, Xiaohong Jing, Weiqing Wang, Benjamin Marks, Ioannis K. Zervantonakis, Anil Korkut, Nicholas P. Gauthier, Chris Sander

    Cancer cells have genetic alterations that often directly affect intracellular protein signaling processes allowing them to bypass control mechanisms for cell death, growth and division. Cancer drugs targeting these alterations often work initially, but resistance is common. Combinations of targeted drugs may overcome or prevent resistance, but their selection requires context-specific knowledge of signaling pathways including complex interactions such as feedback loops and crosstalk. To infer quantitative pathway models, we collected a rich dataset on a melanoma cell line: Following perturbation with 54 drug combinations, we measured 124 (phospho-)protein levels and phenotypic response (cell growth, apoptosis) in a time series from 10 minutes to 67 hours. From these data, we trained time-resolved mathematical models that capture molecular interactions and the coupling of molecular levels to cellular phenotype, which in turn reveal the main direct or indirect molecular responses to each drug. Systematic model simulations identified novel combinations of drugs predicted to reduce the survival of melanoma cells, with partial experimental verification. This particular application of perturbation biology demonstrates the potential impact of combining time-resolved data with modeling for the discovery of new combinations of cancer drugs. Data-driven mathematical modeling of biological systems has enormous potential to understand and predict the interplay between molecular and phenotypic response to perturbation, and provides a rational approach to the nomination of therapy. In cancer, intense effort has focused on drugs that specifically target the machinery involved in tumor development, maintenance and response to therapy. Although many drugs have clinical efficacy in a fraction of patients, the response is rarely durable and patients often develop resistance within months. We believe that the robustness and complexity of living cells, as well as inaccurate assumptions about drug specificity in model systems, underlie the inadequacy of single-agent targeted therapy. In this work, we developed a framework to derive mathematical models of biological systems from molecular and phenotypic temporal responses, and test this framework on melanoma cells. These models are computationally executable and can be used to predict drug combinations likely to be effective at slowing growth or killing cancer cells. Our framework has several advantages: (1) drug specificity is learned, not assumed, during model training, (2) training on temporal (not static) response data improves predictive power, (3) data-driven dynamic models have the potential to accurately reflect a cellular system’s behavior in a context-specific manner.


  • Open Access

    Perturbation biology links temporal protein changes to drug responses in a melanoma cell line

    by Elin Nyman, Richard R. Stein, Xiaohong Jing, Weiqing Wang, Benjamin Marks, Ioannis K. Zervantonakis, Anil Korkut, Nicholas P. Gauthier, Chris Sander

    Data-driven mathematical modeling of biological systems has enormous potential to understand and predict the interplay between molecular and phenotypic response to perturbation, and provides a rational approach to the nomination of therapies in complex diseases such as cancer. Melanoma is a particularly debilitating disease for which most therapies eventually fail as resistance to chemotherapy and targeted drugs develop. We have previously applied an iterative experimental-computational modeling approach, termed perturbation biology, to predict and test effective drug combinations in melanoma cell lines [1]. In this work, we extend our analysis framework to derive models of temporally-acquired perturbation data that do not require prior knowledge and explicit specification of the targets of individual drugs. Specifically, we characterize the response of the melanoma cell line A2058 to 54 cancer drug combinations at 8 logarithmically spaced time points from 10 minutes to 67 hours. At each time point, 124 antibodies of proteins and phospho-proteins with broad coverage of cancer-related pathways and two phenotypes (cell number and apoptosis) were measured. These data are used to infer interactions in ordinary differential equation-based models that capture temporal aspects of the drug perturbation data. This network representation of drug–protein, protein–protein, and protein–phenotype interactions can be used to identify new logical (not necessarily direct biochemical) interactions. The agreement between the predicted phenotypic response and corresponding data for unseen drug perturbations has a Pearson’s correlation coefficient of 0.79. We further use model predictions to nominate effective combination therapies and perform experimental validation of the highest ranked combinations. This new data-driven modeling framework is a step forward in perturbation biology as it incorporates the temporal aspect of data. This work therefore opens the door to a new understanding of dynamic drug responses at a molecular level.


  • Open Access

    Computer-guided design of optimal microbial consortia for immune system modulation

    by Richard R Stein, Takeshi Tanoue, Rose L Szabady, Shakti K Bhattarai, Bernat Olle, Jason M Norman, Wataru Suda, Kenshiro Oshima, Masahira Hattori, Georg K Gerber, et al.

    Manipulation of the gut microbiota holds great promise for the treatment of diseases. However, a major challenge is the identification of therapeutically potent microbial consortia that colonize the host effectively while maximizing immunologic outcome. Here, we propose a novel workflow to select optimal immune-inducing consortia from microbiome compositicon and immune effectors measurements. Using published and newly generated microbial and regulatory T-cell (Treg) data from germ-free mice, we estimate the contributions of twelve Clostridia strains with known immune-modulating effect to Treg induction. Combining this with a longitudinal data-constrained ecological model, we predict the ability of every attainable and ecologically stable subconsortium in promoting Treg activation and rank them by the Treg Induction Score (TrIS). Experimental validation of selected consortia indicates a strong and statistically significant correlation between predicted TrIS and measured Treg. We argue that computational indexes, such as the TrIS, are valuable tools for the systematic selection of immune-modulating bacteriotherapeutics.